Estrogen Dose Equivalence: Patch, Gel, Spray and Pill, and Where the Table Stops Working

Why does an equivalence table exist at all?

Because the question comes up constantly and has a partial answer. Your usual patch is unavailable, a side effect pushes you to change route, or a prescriber suggests a different form. The first thing anyone wants to know is what dose of the new product matches the one they are on.

There is a published answer. It is useful. It is also an approximation built from a different kind of evidence than most people assume, and knowing its limits is what keeps it from misleading you.

What is the standard comparison?

Three products line up at what trials found to be comparable relief of hot flashes and night sweats.

The KEEPS trial compared oral conjugated equine estrogens at 0.45 mg/day directly against a 50 mcg/day patch and found similar relief of vasomotor symptoms, which is part of why clinicians treat the middle row as a working reference. The Canadian Menopause Society publishes a systemic MHT equivalency table covering more products, and it is the kind of document worth taking to an appointment rather than a printout of this page.

Why are these approximations rather than conversions?

Because they come from trials that produced similar symptom relief, not from matched blood levels. The distinction matters more than it sounds.

Swallowed estrogen passes through the liver before reaching the rest of the body. The liver metabolises a large share of it and, in the process, increases production of clotting factors, sex hormone binding globulin, C-reactive protein and thyroid binding globulin. A patch, gel or spray delivers estradiol through the skin straight into the circulation and skips that pass entirely.

So two "equivalent" doses can produce the same number of hot flashes per day while behaving differently everywhere else in the body. The equivalence is about the symptom, not about the drug.

What does the route change that the dose does not?

Clot risk. Vinogradova and colleagues studied 80,396 women aged 40 to 79 with venous thromboembolism against 391,494 matched controls in UK primary care data. Transdermal preparations showed no increased risk (adjusted odds ratio 0.93, 95% CI 0.87 to 1.01), while oral HRT carried a 70% higher risk than transdermal (1.70, 1.56 to 1.85). This is why transdermal is generally preferred for women with migraine with aura, obesity, or a personal or family clot history.

Your testosterone result. Oral estrogen raises sex hormone binding globulin, which binds testosterone and lowers the free fraction even when total testosterone reads normal. If you have been told your testosterone is fine while you feel otherwise, the route you take estrogen by is part of that picture. Our page on SHBG explains the mechanism.

Your inflammatory marker. Oral estrogen raises CRP directly through the same first-pass effect, which can turn a drug effect into an apparent risk signal. See hs-CRP for how that is read.

Your lipid panel. Oral estrogen tends to lower LDL and raise triglycerides; transdermal has much less effect on either. Our guide to reading a lipid panel covers why that matters for interpretation.

Thyroid dosing. Oral estrogen raises thyroid binding globulin, and a woman on levothyroxine may need her dose reviewed after starting it. See thyroid testing.

How do gel, spray and ring fit in?

Equivalence for gels and sprays is less standardised than for patches, because absorption depends on application site, surface area and how much product stays on the skin rather than a towel. Manufacturers publish estradiol content per pump or sachet, but the resulting blood level varies more between people than a patch does.

Practically, this means a switch to gel or spray is made by choosing a starting dose from the product label and adjusting on symptoms after several weeks, not by arithmetic from your patch strength. Both also carry a transfer warning: skin-to-skin contact before the product dries can pass estradiol to a partner, a child or a pet.

Vaginal rings need care because the name covers two different things. A low-dose ring treats genitourinary symptoms locally with minimal systemic absorption and will not touch hot flashes or protect bone. A systemic ring delivers a full body dose. They are not interchangeable, and confusing them during a supply disruption is a genuine error. Our page on vaginal estrogen covers the local products.

How do you know your dose is right?

By how you feel, not by a blood level. Women frequently ask for an estradiol measurement to confirm a dose, and it is a weaker tool than it sounds.

• Levels from patches and gels fluctuate with application site, skin and time since application.
• There is no agreed target level for symptom control. The therapeutic range in menopause is defined by symptoms.
• Standard immunoassays perform poorly at the low concentrations found in postmenopausal women.

Levels do have a place: checking absorption when a woman on an adequate dose still has full symptoms, or when a patch appears not to be working at all. As a routine titration tool, symptoms are better.

"Lowest effective dose" also gets misread. It means the lowest dose that actually controls your symptoms, not the lowest dose on the shelf. Under-treatment is as much a failure as over-treatment, and in practice it is the more common one. Give any change four to eight weeks before judging it: vasomotor symptoms respond within weeks, sleep and mood more slowly, and vaginal symptoms can take months.

What about the progestogen half?

Changing your estrogen form does not change the rule that systemic estrogen in a woman with an intact uterus requires a progestogen to protect the endometrium. The FDA kept the endometrial cancer warning on systemic estrogen-alone products even while removing the cardiovascular, breast cancer and dementia statements from the box in 2026.

If a supply problem forces a change, the progestogen has to be reviewed at the same time rather than left on autopilot. Micronised progesterone, synthetic progestogens and the levonorgestrel intrauterine system are not interchangeable at equal doses, and the route of the estrogen can affect what dose of progestogen is appropriate. See progesterone for menopause and estrogen versus progesterone.

What should you ask at the appointment?

• "My patch is 50 mcg. If we move to gel or spray, what starting dose, and when do we reassess?"
• "Does this change affect my progestogen dose or schedule?"
• "Given my clot and migraine history, is there a reason to stay transdermal?"
• "If supply improves, do I switch back or stay on the new form?"
• "Should my thyroid dose be rechecked if I move to oral?"

If cost is part of the decision, our pages on what HRT costs and insurance coverage cover the practical side, which often decides the route as much as the clinical argument does.

Does the equivalence hold for every reason you take estrogen?

No, and this is the limitation least often stated. The published table matches products on relief of hot flashes and night sweats, because that is the outcome the trials measured. It does not automatically transfer to the other reasons estrogen is prescribed.

For bone protection, the dose needed to preserve bone density is not necessarily the dose that settles vasomotor symptoms, and lower doses that control flushes may do less for the skeleton. If bone is a specific reason you are on treatment, that has to be said out loud during a switch rather than assumed to come along with the symptom relief. See menopause and bone loss.

For genitourinary symptoms, systemic doses that control flushes often do not fully resolve vaginal dryness or urinary symptoms, and local treatment is frequently added alongside. That is not treatment failure, it is two different tissues responding differently.

For premature ovarian insufficiency or surgical menopause, the framing changes completely. The aim is replacing what the ovaries would still be producing until the age of natural menopause, so doses are typically higher than for a woman of 55 managing symptoms, and the standard equivalence table is the wrong starting point.

What about body-identical, bioidentical and compounded products?

Three words that get used interchangeably and should not be.

Body-identical describes regulated products whose molecule matches human estradiol or progesterone: the estradiol in an approved patch, gel or tablet, and micronised progesterone. These are ordinary licensed medicines.

Bioidentical is a marketing term with no regulatory meaning. It is applied both to those licensed products and to compounded preparations, which is exactly why it causes confusion.

Compounded preparations are mixed by a pharmacy to a prescription. They are not FDA-approved, batch potency is not verified the way it is for licensed products, and professional societies advise against them where an approved equivalent exists. Compounded pellets are the clearest example: dosing cannot be adjusted once implanted and cannot be withdrawn if a problem develops.

None of this belongs on an equivalence table, because you cannot equate a verified dose with an unverified one.

What should you write down before you switch?

A switch is easier to judge if you recorded a baseline. Before changing form, note for one week: how many flushes a day, how many night wakings, and how you would rate sleep and mood out of ten. Symptom diaries sound fussy until you are four weeks into a new product trying to remember whether things were worse in March.

Keep the packaging of what you were on, including manufacturer, so the conversation is about a specific product rather than "the patch." And note the date you changed, because attributing a symptom to a switch requires knowing when the switch happened. Our symptom score tool uses a validated scale if you would rather not invent your own.